Obesity is epidemic and dangerous. Weight loss is difficult but worth the effort. Although new weight-loss drugs are available, there are no magic bullets: to lose weight and keep it off, people must eat less and exercise more. This article presents a practical approach on how physicians can help their patients lose weight through diet, behavior modification, and adjunctive pharmacologic therapy.
• OBESITY IS EPIDEMIC
In the United States, 29% of men and 44% of women are trying to lose weight at any given time. 1 Despite these efforts, the chronic disease that is obesity is more prevalent than ever. 2 The body mass index (BMI) quantifies weight across a range of body sizes.It is calculated as the weight in kilograms divided by the square of the height in meters. Alternatively, one can use a readily available nomogram (FIG-URE 1) . The normal range is 18.5 to 24-9 kg/m 2 .
Obesity, defined as a BMI of 30 or higher, is present in about 18% of the US population. 2 Data from the early 1990s showed that 55% of women and 63% of men are overweight (BMI 25 to 29.9) or obese.5
• DANGERS OF OBESITY
Mortality and morbidity increase progressively with a BMI greater than 25 and more steeply with a BMI greater than 30. 6~12 The more overweight a person is, the more likely he or she is to have type 2 diabetes, hypertension, dyslipidemia, coronary artery disease, stroke, obstructive sleep apnea, cor pulmonale, daytime sleepiness without sleep apnea, gout, lower extremity degenerative joint disease, low back pain, lower extremity venous insufficiency, gastroesophageal reflux disease, nonalcoholic steatohepatitis, cholelithiasis, or polycystic ovary syndrome.4.5,13-15 ADVERSE REACTIONS: A total of 771 patients were treated with REMICADE in clinical trials. In both rheumatoid arthritis and Crohn's disease trials, approximately 5% of patients discontinued REMICADE because of adverse experiences. The most common reasons for discontinuation of treatment were dyspnea, urticaria and headache. Infusion-related Reactions Acute infusion reactions An infusion reaction was defined as any adverse event occurring during the infusion or within 1 to 2 hours after the infusion. Seventeen percent of REMICADE-treated patients in all clinical trials experienced an infusion reaction compared to 7% of placebo-treated patients. Among the 3284 REMICADE infusions, 4% were accompanied by nonspecific symptoms such as fever or chills, 1% were accompanied by pruritus or urticaria, 1% were accompanied by cardiopulmonary reactions (primarily chest pain, hypotension, hypertension or dyspnea), and 0.1% were accompanied by combined symptoms of pruritus/urticaria and cardiopulmonary reactions. Less than 2% of patients discontinued REMICADE because of infusion reactions, and all patients recovered with treatment and/or discontinuation of infusion. REMICADE infusions beyond the initial infusion in rheumatoid arthritis patients were not associated with a higher incidence of reactions. Patients with Crohn's disease who became positive for antibodies to infliximab were more likely to develop infusion reactions than were those who were negative (36% vs. 11% respectively). Use of concomitant immunosuppressant agents appeared to reduce the frequency of antibodies to infliximab and infusion reactions (see PRECAUTIONS, Immunogenicity and Drug Interactions). Reactions following readministration In a clinical trial of forty patients with Crohn's disease retreated with infliximab following a 2 to 4 year period without infliximab treatment, 10 patients experienced adverse events manifesting 3 to 12 days following infusion of which 6 were considered serious. Signs and symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients also experiencing pruritus, facial, hand or lip edema, dysphagia, urticaria, sore throat, and headache. Patients experiencing these adverse events had not experienced infusion-related adverse events associated with their initial infliximab therapy. Of the 40 patients enrolled, these adverse events occurred in 9 of 23 (39%) who had received liquid formulation which is no longer in use and 1 of 17 (6%) who received lyophilized formulation. The clinical data are not adequate to determine if occurrence of these reactions is due to differences in formulation. Patients' signs and symptoms improved substantially or resolved with treatment in all cases. There are insufficient data on the incidence of these events after drug-free intervals of less than 2 years. However, these events have been observed infrequently in clinical trials and post-marketing surveillance at intervals of less than 1 year. Infections In REMICADE (infliximab) clinical trials, infections were reported by 26% of REMICADE-treated patients (average of 27 weeks of follow-up) and by 16% of placebo-treated patients (average of 20 weeks of follow-up). The infections most frequently reported were upper respiratory tract infections (including, sinusitis, pharyngitis, and bronchitis) and urinary tract infections. No increased risk of serious infections or sepsis has been observed with Remicade compared to placebo. Among REMICADE-treated patients, these serious infections included pneumonia, cellulitis, pyelonephritis and sepsis. In the ATTRACT study, one patient died with disseminated tuberculosis and one died with disseminated coccidioidomycosis. The relationship to REMICADE is unknown (see WARNINGS, Risk of Infections). Twelve percent of patients with fistulizing Crohn's disease developed a new abscess 8 to 16 weeks after the last infusion of REMICADE. AutoantibodiesAupus-like Syndrome Patients were tested for autoantibodies at multiple time points. In the rheumatoid arthritis ATTRACT study, 23% of REMICADE-treated patients developed antinuclear antibodies (ANA) between screening and last evaluation, compared to 6% of placebotreated patients. Anti-dsDNA antibodies developed in approximately 4% of REMICADE-treated patients, compared to none of the placebo-treated patients. No association was seen between REMICADE dose/schedule and development of ANA or anti-dsDNA. Of Crohn's disease patients treated with REMICADE who were evaluated for antinuclear antibodies (ANA), 34% developed ANA between screening and last evaluation. Anti-dsDNA antibodies developed in approximately 9% of Crohn's disease patients treated with REMICADE. The development of anti-dsDNA antibodies was not related to either the dose or duration of REMICADE treatment. However, baseline therapy with an immunosuppressant in Crohn's disease patients was associated with reduced development of anti-dsDNA antibodies (3% compared to 21% in patients not receiving any immunosuppressant). Crohn's disease patients were approximately 2 times more likely to develop anti-dsDNA antibodies if they were ANA-positive at study entry. Three patients developed clinical symptoms consistent with a lupus-like syndrome, two with rheumatoid arthritis and one with Crohn's disease. All three patients improved following discontinuation of therapy and appropriate medical treatment (see PRECAUTIONS, Autoimmunity). Mallgnancies/Lymphoprolileratiye Disease Five new and 2 recurrent malignancies were observed in 6 of 771 patients treated with REMICADE for up to 36 weeks in clinical trials. These were nonHodgkin's B-cell lymphoma, breast cancer, melanoma, squamous cell cancer of the skin, and basal cell cancer. There are insufficient data to determine whether REMICADE contributed to the development of these malignancies. The observed rates and incidences were similar to those expected for the populations studied" (see PRECAUTIONS, Malignancy). Other Adverse Reactions Adverse events occurring at a frequency of at least 5% In trials in patients with rheumatoid arthritis or Crohn's disease are shown in the table below. Patients with Crohn's disease who were treated with REMICADE were more likely than patients with rheumatoid arthritis to experience adverse events associated with gastrointestinal symptoms. Nausea  17%  14%  4%  17%  Abdominal Pain  7%  8%  4%  12%  Vomiting  10%  5%  0%  9%  Other  Headache  10%  20%  21%  23%  Rash  4%  9%  5%  6%  Fatigue  5%  6%  5%  11%  Fever  4%  6%  7%  10%  Back pain  2%  6%  4%  5%  Pain  4%  6%  5%  9%  Urinary tract infection  3%  6%  4%  3%  Pruritus  0%  5%  2%  5%  Moniliasis  2%  3%  0% Obese persons have a higher mortality rate from cancers of the biliary tract, ovary, endometrium, and cervix in women and from cancers of the colon and prostate in men. 16 An estimated 300,000 deaths each year in the United States are attributable to obesityand this is a conservative figure. 17 Obese persons are also more likely to have impaired quality erf life and disability, 18 -19 and their health care costs arc more than 25% higher compared with the nonobese. 20 
ADVERSE EVENTS IN RHEUMATOID ARTHRITIS AND CROHN'S RHEUMATOID ARTHRITIS

DISEASE TRIALS CROHN'S DISEASE
Lower body fat vs central body fat
But not all obese persons carry the same risk of adverse outcome. In persons with a BMI less than 35, gluteofemoral or lower body adiposity is not as worrisome as is abdominal or centrally distributed fat. Waist circumference has been shown to be an independent risk factor for the diseases associated with obesity. A waist circumference greater than 40 inches in men or 35 inches in women places the patient at high risk. 3 Patients with a BMI less than 35 should have their waist measured at the narrowest area between the lowest rib and the iliac crest. The "waist" does not always correspond to the level of the umbilicus.
Patients with a BMI of 35 or greater are at high risk irrespective of waist measurement. In these patients, it is not necessary to record the waist measurement, as this information would not affect prognosis.
• MODEST WEIGHT LOSS IS BENEFICIAL
Do obese patients who lose weight live longer? Although there are no prospective randomized trials proving that weight loss reduces mortality, considerable indirect data support such a conclusion. One large, prospective, observational study in nonsmoking women found a 20% reduction in all-cause mortality in those who had intentionally lost weight. 21 Weight loss also appears to reduce the likelihood of developing type 2 diabetes and reduces risk factors for coronary artery disease. Loss of 5% to 10% of baseline weight usually leads to lower triglycerides, blood pressure, and left ventricular mass. 22 
Perform a history and physical examination
All obese patients for whom treatment is contemplated need a thorough history and physical examination to clarify the severity of obesity and the comorbid conditions that can be expected to improve with weight loss.
Obtain a weight history and include previous weight-loss efforts. Keep in mind that substantial weight gain may be associated with pregnancy, major life stresses, reduced physical activity, tobacco cessation, depression and certain medications (eg, glucocorticoids, valproate, and some antipsychotic agents).
The family history should elucidate any family history erf obesity and associated disorders (eg, diabetes, coronary artery disease).
Identify the eating pattern for a typical day, as well eating in response to certain emotional states.
The exercise history and obstacles to exercise should be assessed.
Screen all obese patients for depression, which is common in this setting. Obesity should not be invoked as a "reason" for depression or used as an excuse not to treat depression. Screening questions for depression that are simple, nonthreatening, and validated 23 In addition, it is reasonable to obtain a thyroid-stimulating hormone level to screen for hypothyroidism. Cushing syndrome is uncommon but easily missed; if suspected, a 24-hour urine sample should be obtained to measure free Cortisol and creatinine. Overnight dexamethasone suppression testing may also help in this setting.
• WHAT ARE REALISTIC GOALS?
The initial goal is to lose 5% to 10% of the baseline weight. 3 This goal needs to be discussed openly because obese patients often have unrealistic expectations of magically achieving a "dream" weight.
The weight loss plan devised should improve upon previous plans: for example, implementing a regular, convenient exercise program that had not been included in the past, or offering pharmacotherapy.
Advise the patient that it may take 3 to 6 months to reach the initial weight-loss goal. Furthermore, any therapy instituted or changes made will need to be continued to keep the lost weight off. Reverting to previous behavior, going back to old eating habits, or stopping effective medication will all lead to gaining weight back. 
• PRESCRIBE DIETTHERAPY
INDICATIONS AND USAGE Hypertension
Toprol-XL tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Toprol-XL tablets are indicated in the long-term treatment of angina pectoris.
CONTRAINDICATIONS Hypertension and Angina
Toprol-XL is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see WARNINGS).
WARNINGS Hypertension and Angina
Cardiac Failure: Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta-blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics,Toprol-XL should be administered cautiously. Both digitalis and Toprol-XL slow AV conduction. In Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully diaitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, Toprol-XL should be withdrawn.
Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Toprol-XL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Toprol-XL administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Toprol-XL therapy abruptly even in patients treated only for hypertension.
Bronchospastic
Diseases: PATIENTS WITH BRONCHOSPASTIC DIS-EASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta!-selectivity, however, Toprol-XL may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since beta!-selectivity is not absolute, a betao-stimulating agent should be administered concomitantly, and the lowest possible dose of Toprol-XL should be used (see DOSAGE AND ADMINISTRATION). Major Surgery: The necessity or desirability of withdrawing beta-blocking therapy prior to major surgery is controversial; the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Toprol-XL like other beta-blockers, is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol, However, such patients may be subject to protracted severe hypotension. Difficulty in restarting and maintaining the heart beat has also been reported with beta-blockers. Diabetes and Hypoglycemia: Toprol-XL should be used with caution in diabetic patients if a beta-blocking agent is required. Beta-blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected. Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of betablockade, which might precipitate a thyroid storm.
PRECAUTIONS General
Toprol-XL should be used with caution in patients with impaired hepatic function.
Information for Patients
Patients should be advised to take Toprol-XL regularly and continuously, as directed, preferably with or immediately following meals. If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). Patients should not discontinue Toprol-XL without consulting the physician. Patients should be advised (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's 200 mg
Convenience Compliance
Consistent 24-Hour ß,-Blockade
response to therapy with Toprol-XL has been determined; (2) to contact the physician if any difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking Toprol-XL.
Laboratory Tests
Clinical laboratory findings may include elevated levels of serum transaminase, alkaline phosphatase, and lactate dehydrogenase.
Drug Interactions
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with Toprol-XL plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have been conducted to evaluate the carcinogenic potential of metoprolol tartrate. In 2-year studies in rats at three oral dosage levels of up to 800 mg/kg/day, there was no increase in the development of spontaneously occurring benign or malignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli and a slight increase in biliary hyperplasia. In a 21-month study in Swiss albino mice at three oral dosage levels of up to 750 mg/kg/day, benign lung tumors (small adenomas) occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total (benign plus malignant) lung tumors, nor in the overall incidence of tumors or malignant tumors. This 21-month study was repeated in CD-1 mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type of tumor. All mutagenicity tests performed on metoprolol tartrate (a dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nucleus anomaly test in somatic interphase nuclei) and metoprolol succinate (a Salmonella/mammalian-microsome mutagenicity test) were negative. No evidence of impaired fertility due to metoprolol tartrate was observed in a study performed in rats at doses up to 55.5 times the maximum daily human dose of 450 mg.
Pregnancy Category C Metoprolol tartrate has been shown to increase post-implantation loss and decrease neonatal survival in rats at doses up to 55.5 times the maximum daily human dose of 450 mg. Distribution studies in mice confirm exposure of the fetus when metoprolol tartrate is administered to the pregnant animal. These studies have revealed no evidence of impaired fertility or teratogenicity. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers
Metoprolol is excreted in breast milk in very small quantities. An infant consuming 1 liter of breast milk daily would receive a dose of less than 1 mg of the drug. Caution should be exercised when Toprol-XL is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Risk Of Anaphylactic Reactions
While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
ADVERSE REACTIONS Hypertension and Angina
Most adverse effects have been mild and transient. The following adverse reactions have been reported for metoprolol tartrate. Central Nervous System: Tiredness and dizziness have occurred in about 10 of 100 patients. Depression has been reported in about 5 of 100 patients. Mental confusion and short-term memory loss have been reported. Headache, somnolence, nightmares, and insomnia have also been reported.
Cardiovascular:
Shortness of breath and bradycardia have occurred in approximately 3 of 100 patients. Cold extremities; arterial insufficiency, usually of the Raynaud type; palpitations; congestive heart failure; peripheral edema; syncope; chest pain; and hypotension have been reported in about 1 of 100 patients (see CONTRAINDICATIONS, WARNINGS and PRECAUTIONS). Respiratory: Wheezing (bronchospasm) and dyspnea have been reported in about 1 of 100 patients (see WARNINGS).
Gastrointestinal: Diarrhea has occurred in about 5 of 100 patients. Nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders and heartburn have been reported in about 1 of 100 patients. Hypersensitive Reactions: Pruritus or rash have occurred in about 5 of 100 patients. Worsening of psoriasis has also been reported. Miscellaneous: Peyronie's disease has been reported in fewer than 1 of 100,000 patients. Musculoskeletal pain, blurred vision, decreased libido and tinnitus have also been reported. There have been rare reports of reversible alopecia, agranulocytosis, and dry eyes. Discontinuation of the drug should be considered if any such reaction is not otherwise explicable. The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with metoprolol. Potential Adverse Reactions A variety of adverse reactions not listed above have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to Toprol-XL. Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. Cardiovascular: Intensification of AV block (see CONTRAINDICATIONS). Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura. Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm, and respiratory distress.
OVERDOSAGE Acute Toxicity
There have been a few reports of overdosage with Toprol-XL and no specific overdosage information was obtained with this drug, with the exception of animal toxicology data. However, since Toprol-XL (metoprolol succinate salt) contains the same active moiety, metoprolol, as conventional metoprolol tablets (metoprolol tartrate salt), the recommendations on overdosage for metoprolol conventional tablets are applicable to Toprol-XL.
Signs and Symptoms
Potential signs ana symptoms associated with overdosage with metoprolol are bradycardia, hypotension, bronchospasm, and cardiac failure.
Treatment
There is no specific antidote. In general, patients with acute or recent myocardial infarction may be more hemodynamically unstable than other patients and should be treated accordingly. On the basis of the pharmacologic actions of metaprolol tartrate, the following general measures should be employed. Elimination of the Drug: Gastric lavage should be performed. Bradycardia: Atrophine should be administered. If there is no response to vagal blockade, isoproterenol should be administered cautiously. Hypotension: A vasopressor should be administered, eg., levarterenol or dopamine. Bronchospasm: A beta2-stimulating agent and/or a theophylline derivative should be administered. Cardiac Failure: A digitalis glycoside and diuretics should be administered. In shock resulting from inadequate cardiac contractility, administration of dobutamine, isoproterenol or glucagon may be considered. DOSAGE AND ADMINISTRATION Toprol-XL is an extended release tablet intended for once-a-day administration. When switching from immediate release metoprolol tablet to Toprol-XL, the same total daily dose of Toprol-XL should be used. As with immediate release metoprolol, dosages of Toprol-XL should be individualized and titration may be needed in some patients. Toprol-XL tablets are scored and can be divided; however, the whole or half tablet should be swallowed whole and not chewed or crushed. Hypertension The usual initial dosage is 50 to 100 mg daily in a single dose, whether used alone or added to a diuretic. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. Dosages above 400 mg per day have not been studied.
Angina Pectoris
The dosage of Toprol-XL should be individualized. The usual initial dosage is 100 mg daily, given in a single dose. The dosage may be gradually increased at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1-2 weeks (see WARNINGS). claim is a nonchallenging "I'm sure you do, but you've got to eat less if you want to lose weight." Obese persons have been documented to eat more than they report, especially more fat; this is termed underreporting. In contrast, when they keep a food diary they tend to eat less than they do when not keeping a food diary; this is termed undereating. 2 
HOW SUPPLIED
4,25
The calorie intake and metabolic rate (and in turn, daily energy expenditure) of most obese persons are not low.
For weight loss, calorie expenditure must exceed intake The resting energy expenditure 26 in kilocalories can be estimated using the following formulae:
• In men: 10 X (current weight in kg) + 900 • In women: 7 X (current weight in kg) + 800
Multiplying the results by 1.2 gives an estimate of 24-hour calorie requirements for a sedentary lifestyle.
A calorie deficit of 500 to 1,000 kcal/day leads to loss of about 1 to 2 lb/week. Weight loss may plateau at about 6 months, primarily owing to decreased energy expenditure.
Patients should consume at least 800 kcal/day. There is no clear benefit from diets containing less than 800 kcal/day, ie, the socalled very-low-calorie diets. [27] [28] [29] If less than 1,000 calories per day are consumed, care should be taken to provide enough protein of high biologic value, at least 0.8 gm/kg of ideal body weight per day. (To calculate the ideal body weight in this setting, take the patients height in meters, square it, and then multiply times 24-the result would be the patient's weight at a body mass index of 24.) Adequate protein intake preserves lean body mass. Consultation with a dietitian may be indicated. However, very few patients need to reduce calorie intake to less than 1,000 calories per day to lose weight.
Weight loss will occur only if calorie intake is less than expenditure. No special foods alter this fact. Diets should be balanced to provide essential nutrients consistent with the food pyramid and accepted dietary guidelines (eg, from the American Heart Association, American Diabetes Association, and American Dietetic Association).
Limit fats, not just calories
No more than 30% of the total calorie intake should come from fats. Excess calories from fat are more likely to lead to fat accumulation than are excess calories from carbohydrates, because fat is stored as fat with little energy needed for storage. Carbohydrates, on the other hand, must first be converted to fat for storage. This biochemical transformation requires substantial energy, about 20% of the excess carbohydrate calories consumed. 30 Patients who count both fat and total calorie intake rather than calories alone are more successful at weight loss. 31 ' 32 Fat is much more calorie-dense than carbohydrate, containing 9 calories per gram vs 4 per gram.
Provide an eating plan
Making new food choices is challenging for obese patients who have established their eating habits and preferences over years. Written, detailed meal plans aid weight-loss efforts. Low-calorie frozen entrees can also help. 33 > 3 4 No foods need be strictly forbidden, although some patients find it difficult to control the quantity of certain foods. Such foods may be best avoided until restraint and coping techniques are enhanced.
Olestra, a sucrose polyester, may be of some benefit in reduced-calorie meal plans. Wellperformed short-term studies demonstrated an overall reduction in calorie and fat intake when olestra-containing snacks replaced conventional fat snacks. 35 -36 There are no long-term data showing reduced calorie intake with olestra snacks, however.
Diet fads and myths
High-fat, low-carbohydrate diets, which are receiving renewed interest by the public, lack evidence of long-term benefit. Multiple studies showed that people take in more calories when they consume fat ad lib than when they consume carbohydrates ad lib. Some studies showed weight loss with low-fat (30% of calories) and ad lib carbohydrate intake. 37 In addition, high-fat low-carbohydrate diets are unbalanced, and people do not adhere to them well in the long term.
High-protein intakes are given to those few patients prescribed less than 800 calories per day. One such approach to this proteinAim for a calorie deficit of 500 to 1,000 kcal/day OBESITY WEISS sparing modified fast is the use of natural foods such as lean fish, fowl, or red meat with little or no carbohydrate. Other approaches use a commercially available mixed formula powder that is reconstituted with liquid. These formulas may differ in their carbohydrate content. No scientific evidence supports any particular very-low-calorie diet over another. Great care must be taken to ensure that adequate vitamin and mineral intake is provided on these diets.
Drinking lots of water. Another popular recommendation that has no demonstrated benefit in weight loss is to drink 6 to 8 glasses of water daily. No changes in calorie intake have been shown with increased water consumption before meals. 38 Number and size of meals per day. In terms of weight loss, there is no proven advantage to eating three meals per day vs fewer meals. Many obese persons habitually skip breakfast, eat a small lunch, and then eat from supper until bedtime. Although patients may be more inclined to eat breakfast if they were to stop eating in the evening, an obese person should never be advised to eat when he or she is not hungry.
Any activity is
• WHY EXERCISE IS ESSENTIAL better than . .
Dietary changes are not enough; exercise is
none at all
essential. An obese person should exercise regularly because:
• Those who exercise regularly have greater cardiorespiratory fitness and appear to be at reduced risk of cardiovascular events and mortality.« • Regular exercise, by increasing the calorie deficit, may modestly increase the amount of weight lost when coupled with reduced calorie intake.
• Exercise during weight loss helps retain muscle that would be lost if the person were not to exercise. 40 • Exercise is perhaps the most important predictor of long-term maintenance of weight loss.4l.42
Prescribing exercise
The American College of Sports Medicine and the Centers for Disease Control and Prevention recommend 30 minutes or more of moderately intense physical activity such as brisk walking at least 5 days per week. 43 Fewer than 25% of US adults get this much exercise, and about another 25% are completely sedentary. Only 20% of obese men and 15% of obese women engage in this degree of activity in addition to calorie restriction during their weight-loss efforts. 1 It is unreasonable, however, to expect sedentary obese persons to move from inactivity to this amount of exercise. Any activity is better than none at all. As with any behavioral change, small steps are more easily accomplished. For example, have your patient start walking three to four times a week for 10 minutes, and over the ensuing weeks gradually increase the duration and frequency. Consider exercise stress testing to assess for coronary artery disease in sedentary patients at high risk, such as those with type 2 diabetes.
Exercise does not have to be vigorous to be of value for weight loss. However, a recent study44 suggested that people may need to exercise longer and harder than the current recommendations if they wish to keep lost weight off: 60 to 80 minutes per day of moderately intense exercise or 35 minutes per day of vigorous exercise may be needed. The total duration of exercise, weekly and daily, is more important for weight loss than whether it is done in short (10-minute) bouts throughout the day or one longer period of 40 minutes. 45 Discuss a realistic exercise program with your patient. The exercise chosen should be convenient and acceptable to your patient. Patients appear more likely to exercise when they have access to home equipment. 43 Options include walking (outside or in an indoor shopping mall), riding a stationary cycle, walking on a treadmill, or performing low-impact aerobic exercise with a video or in a class. Those who plan to walk outdoors must have an alternative for inclement weather, otherwise they'll have an excuse for not exercising up to half the year in some parts of the United States.
Although daily activity should be distinguished from scheduled aerobic exercise, all activity is of value. 46 For example, parking the car farther away from the building entrance, taking the stairs, walking the dog, or cleaning the house are all helpful in weight management. Carcinogenesis, Mutagenesis, and Impairment of Fertility Rats administered doses up to 43 mg/kg/day in males and 52 mg/kg/day in females had no increases in tumor incidence with the exception of a modest increase in the frequency of mammary gland fibroadenomas in female rats receiving doses > 5.4 mg/kg (P < 0.015). The highest doses of tamsulosin HCI evaluated in the rat carcinogenicity study produced systemic exposures (AUC) in rats 3 times the exposures in men receiving the maximum therapeutic dose of 0.8 mg/day. Mice were administered doses up to 127 mg/kg/day in males and 158 mg/kg/day in females. There were no significant tumor findings in male mice. Female mice treated for 2 years with the two highest doses of 45 and 158 mg/kg/day had statistically significant increases in the incidence of mammary gland fibroadenomas (P< 0.0001) and adenocarcinomas (P< 0.0075). The highest dose levels of tamsulosin HCI evaluated in the mice carcinogenicity study produced systemic exposures (AUC) in mice 8 times the exposures in men receiving the maximum therapeutic dose of 0.8 mg/day.
FLOMAX TAMSULOSIN HCl 1
The increased incidences of mammary gland neoplasms in female rats and mice were considered secondary to tamsulosin HCI-induced hyperprolactinemia. It is not known if FLOMAX capsules elevate prolactin in humans. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is not known. Tamsulosin HCI produced no evidence of mutagenic potential in vitro in the Ames reverse mutation test, mouse lymphoma thymidine kinase assay, unscheduled DNA repair synthesis assay, and chromosomal aberration assays in Chinese hamster ovary cells or human lymphocytes. There were no mutagenic effects in the in vivo sister chromatid exchange and mouse micronucleus assay. Studies in rats revealed significantly reduced fertility in males dosed with single or multiple daily doses of 300 mg/kg/day of tamsulosin HCI (AUC exposure in rats about 50 times the human exposure with the maximum therapeutic dose). The mechanism of decreased fertility in male rats is considered to be an effect of the compound on the vaginal plug formation possibly due to changes of semen content or impairment of ejaculation. The effects on fertility were reversible showing improvement by 3 days after a single dose and 4 weeks after multiple dosing. Effects on fertility in males were completely reversed within nine weeks of discontinuation of multiple dosing. Multiple doses of 10 and 100 mg/kg/day tamsulosin HCI (1/5 and 16 times the anticipated human AUC exposure) did not significantly alter fertility in male rats. Effects of tamsulosin HCI on sperm counts or sperm function have not been evaluated. Studies in females rats revealed significant reductions in fertility after single or multiple dosing with 300 mg/kg/day of the R-isomer or racemic mixture of tamsulosin HCI, respectively. In female rats, the reductions in fertility after single doses were considered to be associated with impairments in fertilization. Multiple dosing with 10 or 100 mg/kg/day of the racemic mixture did not significantly alter fertility in female rats. ADVERSE REACTIONS The incidence of treatment-emergent adverse events has been ascertained from six shortterm U.S. and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg FLOMAX capsules were used. These studies evaluated safety in 1783 patients treated with FLOMAX capsules and 798 patients administered placebo. Table 3 summarizes the treatment-emergent adverse events that occurred in > 2% of patients receiving either FLOMAX capsules 0.4 mg, or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men. 1 A treatment-emergent adverse event was defined as any event satisfying one of the following criteria:
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• The adverse event occurred for the first time after initial dosing with double-blind study medication.
• The adverse event was present prior to or at the time of initial dosing with double-blind study medication and subsequently increased in severity during double-blind treatment; or • The adverse event was present prior to or at the time of initial dosing with double-blind study medication, disappeared completely, and then reappeared during double-blind treatment. Multiple testing for orthostatic hypotension was conducted in a number of studies. Such a test was considered positive if it met one or more of the following criteria: (1) a decrease in systolic blood pressure of >20 mmHg upon standing from the supine position during the orthostatic tests; (2) a decrease in diastolic blood pressure >10mmHg upon standing, with the standing diastolic blood pressure <65 mmHg during the orthostatic test; (3) an increase in pulse rate of >20 bpm upon standing with a standing pulse rate >100 bpm during the orthostatic test; and (4) Because orthostasis was detected more frequently in FLOMAX capsule-treated patients than in placebo recipients, there is a potential risk of syncope (see WARNINGS). Abnormal Ejaculation Abnormal ejaculation includes ejaculation failure, ejaculation disorder, retrograde ejaculation and ejaculation decrease. As shown in Table 3 , abnormal ejaculation was associated with FLOMAX capsules administration and was dose-related in the U.S. studies. Withdrawal from these clinical studies of FLOMAX capsules because of abnormal ejaculation was also dose-dependent with 8 of 492 patients (1.6%) in the 0.8-mg group, and no patients in the 0.4-mg or placebo groups discontinuing treatment due to abnormal ejaculation. Muscle strengthening using resistive weight training is less well studied in obesity management. This form of exercise does appear to be of value in maintaining lean body mass.4' However, data are insufficient to show benefit in the other three aspects for which aerobic exercise is clearly beneficial (reducing cardiovascular risk, increasing weight loss, or maintaining weight loss).
Signs and Symptoms of Orthostasis
Post-Marketing Experience
• BEHAVIOR MODIFICATION
Current treatments for obesity all require some modification of behavior for success. The changes in eating and activity described above can only be accomplished with awareness and understanding sufficient to modify one's current lifestyle.48 Books and manuals. A variety of approaches have been used. Workbooks and self-help manuals are available. In one study (in which patients also received an antiobesity medication), l5-to-20-minute visits with a physician were as effective as a more-intensive, more-frequent traditional group approach to behavior modification. 49 In both interventions, patients used the LEARN Manual for Weight Control. 50 This is a very useful, practical workbook that can be used with patients in a group or one-on-one interactions. On the other hand, pharmacotherapy without guidance in making lifestyle changes is less effective than the combination of both methods.
Food diary. Self-monitoring is one method used in behavior modification. One type of self-monitoring-keeping a food diary has been proven to increase weight loss. 
• USE PHARMACOTHERAPY AS AN ADJUNCT
Pharmacotherapy for obesity can be considered for a patient who:
• Is committed and able to make changes in eating and activity necessary for weight loss, and • Has a BMI of 30 or greater or a BMI greater than 27 with weight-related comorhid conditions. 5 ' 28 Drug therapy should be used as an adjunct to diet, exercise, and behavior modification; it should not be used in isolation. Some state medical boards place additional restrictions on prescribing drugs for obesity. No drugs for weight loss should be prescribed during pregnancy or lactation.
Treat depression before beginning medication for obesity. Depression impairs function and, if untreated, impedes weight-loss efforts. 51 Of the antidepressants, bupropion appears least likely to be associated with weight gain; indeed, it often causes modest weight loss. Nefazodone, venlafaxine, and most of the selective serotonin reuptake inhibitors are better choices in obese patients than are tricyclic antidepressants.
Duration of drug therapy. Decades ago, when the FDA originally approved the older anorectic agents, they were to be used only for "a few weeks." However, we now understand that obesity is a chronic disease. To be effective, drug treatment for obesity should be continued indefinitely. 52 
Sibutramine
Sibutramine (Meridia), the newest of the anorectic agents, has been extensively studied for up to 2 years of treatment. However, it has not been shown to be any more effective than other anorectic agents currently available. Sibutramine acts by inhibiting reuptake of norepinephrine and serotonin in the central nervous system without promoting the release of these neurotransmitters. Effectiveness. In a multicenter study, 54 1,047 patients were randomized to receive differing doses of sibutramine or placebo for 24 weeks. Only 683 patients completed the study; this high (35%) dropout rate is common in obesity studies. All patients received counseling in diet, exercise, and behavioral change. At baseline, the mean BMI was 34-5. In an analysis that included all patients randomized including those who dropped out (a so-called "last observation carried forward" [LOCF] analysis), the group receiving placebo lost 0.9% of their baseline weight, compared with 4-7% in the sibutramine 10-mg group and 5.8% in the 15-mg group.
An analysis of patients who actually completed 24 weeks of treatment showed more favorable results. Of those taking sibutramine
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If a patient does not lose 4 lb in 4 weeks, stop the drug stopped, the condition for which it was prescribed will reappear; high blood pressure recurs when an antihypertensive is stopped. Likewise, weight is usually regained when the antiobesity drug is discontinued. No drugs "cure" obesity. The balance of risk vs benefits must be addressed when anorectic agents are prescribed. One placebo-controlled study with double-blind and open-label periods showed benefit of anorectic agents in a small group of patients followed for more than 3 1/2 years. 55 The efficacy of these agents was demonstrated repeatedly when the patients regained weight after the drugs were stopped and resumed losing weight when back on drug therapy.
As with other medications, patient responses to antiobesity agents are quite mixed. In general, failure to achieve the initial goal of a weight loss of 5% to 10% of the baseline weight within 3 to 6 months is an indication to stop the medication. However, a plateau in weight after 6 to 9 months is expected and is not cause for stopping the drug.
Currently available prescription medications for obesity work via one of two mechanisms, as discussed below. Six anorectic agents, which result in reduced food intake, are currently available (TABLE 2) . and 17% lost 10% of their baseline weight. Of those taking 15 mg, 67% lost 5% of their baseline weight and 35% lost 10% of their baseline weight. Of those receiving placebo, 20% lost 5% and none lost 10%.
However, even among patients taking sibutramine 15 mg-the maximum recommended dose-30% of patients did not lose even 5% of their baseline weight. The initial response to treatment can identify this group early. Patients who do not lose at least 4 lb over the first 4 weeks of treatment (20%-25% of the group in the studies) are not likely to lose 5% by 6 months (83% of this group did not) and should therefore stop the drug after 4 weeks.
Studies showed that sibutramine retains its effectiveness in responders for up to 2 years. Most of these data are not yet published. In one published 12-month study, 55 sibutramine was substantially more effective than placebo in maintaining weight lost after 4 weeks of a very-low-calorie diet.
Adverse effects. The most common adverse effects of sibutramine are dry mouth, constipation, and insomnia. No evidence of abuse potential is seen. 56 Dose-dependent mean increases of 3 to 4 mm Hg in both systolic and diastolic blood pressure occur. Dose-dependent heart rate increases averaging 6 heats per minute also occur. These changes may he more substantial in some patients hut infrequently necessitate stopping the drug.
Echocardiography has shown no increase in cardiac valvular abnormalities with sibutramine, 57 unlike that seen with fenfluramine and dexfenfluramine, serotoninreleasing agents withdrawn from the market in 199 7. 58 Whether this is because sibutramine has a somewhat different mechanism of action (inhibiting norepinephrine and serotonin reuptake rather than promoting serotonin release, as with the earlier agents) is not known.
Primary pulmonary hypertension is a rare disorder that has been associated with anorectic agents, especially fenfluramine derivatives. The background incidence of this disorder in the general population is estimated at 1 to 2 cases per million persons per year. 59 Patients treated with fenfluramine or dexfenfluramine had an estimated incidence of 25 cases per million persons treated per year. 59 No increase in the incidence of primary pulmonary hypertension has been seen thus far with sibutramine.
Contraindications to the use of sibutramine include coronary artery disease, congestive heart failure, stroke, arrhythmia, severe liver or kidney disease, uncontrolled hypertension, and seizure disorders. Other contraindications include treatment with serotonergic migraine medications, monoamine oxidase inhibitors, or other medications active in the central nervous system, including antidepressants and other anorectic agents. There are no data on safety and efficacy in patients younger than 16 years, and few data for those older than 65 years.
Dosage. Sibutramine is available as 5-mg, 10-mg, and 15-mg capsules. The usual starting dose is 10 mg. The 5-mg dose is reserved for those with side effects at the 10-mg dose. The maximum recommended dose is 15 mg/day.
Cost. The average wholesale price in the United States is $2.90 for a 10-mg capsule, and $3.75 for the 15-mg capsule.
Support program. The manufacturer provides a telephone and newsletter-type support program to patients taking sibutramine. 52 are far les?
Older anorectic agents
Other anorectic agents (TABLE 2) costly than sibutramine. Most of these drugs, however, were studied only in small trials lasting no more than 12 weeks. One study in 72 patients found that phentermine resin was significantly more beneficial than placebo during 36 weeks of therapy; this was the longest-running monotherapy trial of the older agents. Intermittent therapy (on drug 1 month, off the next) was as effective as continuous therapy. Another study found the combination of phentermine and fenfluramine better than placebo during more than 3 years of therapy. 53 The combination of ephedrine (an adrenergic agonist, 60 mg/day) with caffeine (600 mg/day) was studied in a limited fashion. 60 This combination is not FDA-approved, but ephedrine-caffeine combinations are sold over-the-counter in herbal preparations. Although many people use them, they may lack consistent reliable doses of ephedrine and cause unpredictable adverse cardiovascular effects.
Orlistat
Orlistat (Xenical) acts by a completely different mechanism: inhibiting intestinal lipase activity. Orlistat binds covalently to the active site of the enzyme, making it unavailable to hydrolyze dietary fat in the form of triglycerides. Therefore, 30% of fat is unabsorbed and passes into the colon. There is minimal (< 1%) systemic absorption of the drug.
Effectiveness. Two large placebo-controlled trials documented the efficacy of orlistat use for up to 2 years. 61 ' 62 A total of 1,580 patients were randomized. In both trials the diet was adjusted to maintain weight after 1 year. After 1 year, the orlistat group lost 10.2% of body weight in one study and 8.8% in the other; in comparison, patients in the placebo groups lost 6.1% and 5.8%. Thirtynine percent of orlistat-treated patients lost more than 10% of their initial weight, compared with 25% of the placebo group. At 2 years, weight loss with orlistat was 7.6% compared with 4-5% with placebo. After 2 years, twice as many patients taking orlistat (34% vs 17%) maintained a weight loss of more than 10%. Likewise, twice as many patients taking orlistat lost at least 5% of their weight (about 50% compared with 25% in the placebo group).
These and other 1-year studies 65 ' 64 demonstrated less weight regain with orlistat than with placebo, and small but statistically significant improvements in lipids, glycemic control, and blood pressure. Pooled data reveal that patients who lose less than 3% of their initial weight at 12 weeks (approximately 30% of those completing the studies) are unlikely to lose 5% or more of their weight by 52 weeks.
Adverse effects of orlistat relate to its mechanism of action. Patients may experience flatus with discharge, oily spotting, fecal urgency, increased stool frequency, and occasional fecal incontinence. These effects can be avoided by limiting fat in the diet to 30% of calories distributed over three meals. Symptoms are usually minimal and diminish with time as patients modify their diet.
Patients need specific dietary instruction and should count how many grams of fat they consume.
No drug interactions have been reported with orlistat. The only contraindications to its use are chronic malabsorption and cholestasis, which are unlikely settings for obesity. Slight decreases in serum levels of fat-soluble vitamins have been seen but usually not below the normal range. However, patients should take a multivitamin supplement daily at least 2 hours before or after taking orlistat.
Dosage. Orlistat 120 mg should be taken no more than three times per day, during or up to 1 hour after each main meal. There is no benefit to increasing the dosage above 360 mg/day, and there is no reason to take a dose if a meal contains no fat. If the meal is skipped, the orlistat should be skipped.
Cost is $1.32 per capsule or about $4 a day if taken three times a day.
Support program. The manufacturer sponsors a support program for patients taking orlistat.
• BARIATRIC SURGERY
For a small number of severely obese patients for whom repeated attempts at weight loss have failed, surgery may be a reasonable option. 65 Patients with a BMI of 40 or greater or those with a BMI greater than 35 with multiple comorbidities may be appropriate candidates.
The Roux-en-Y gastric bypass procedure appears to be most effective and safest longterm. This procedure divides the stomach into a small proximal pouch and a larger excluded fundus and antrum. The pouch has a capacity of 30 to 60 mL and is attached directly to the jejunum via a narrow anastomosis. The small pouch volume produces early satiety, and the narrow anastomosis delays pouch emptying.
Candidates must be carefully selected and counseled regarding the lifelong changes in eating necessary after surgery. At 5 years,
BRIEF SUMMARY-ARTHROTEC® (diclofenac sodium and misoprostol)
Before prescribing, please consult complete prescribing information. ® CONTRAINDICATIONS AND WARNINGS ARTHROTEC 9 , because of the abortifacient property of the misoprostol component, is contraindicated in women who are pregnant. (See PRECAUTIONS.) Reports, primarily from Brazil, of congenital anomalies and reports of fetal death subsequent to misuse of misoprostol alone, as an abortifacient, have been received. Patients must be advised of the abortifacient property and warned not to give the drug to others. ARTHROTEC should not be used in women of childbearing potential unless the patient requires nonsteroidal anti-inflammatory drug (NSAID) therapy and is at high risk of developing gastric or duodenal ulceration or for developing complications from gastric or duodenal ulcers associated with the use of the NSAID. (See WARNINGS.) In such patients, ARTHROTEC may be prescribed if the patient:
• has had a negative serum pregnancy test within two weeks prior to beginning therapy.
• is capable of complying with effective contraceptive measures.
• has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbeartng potential should the drug be taken by mistake.
• will begin ARTHROTEC only on the second or third day of the next normal menstrual period. In a 24-mo rat carcinogenicity study, oral misoprostol at doses up to 24x the recommended maximum human dose of 0.6 mg/m 2 /day was not tumorigenic. In a 21-mo mouse carcinogenicity study, oral misoprostol at doses up to 80x the recommended maximum human dose was not tumorigenic. Misoprostol, when administered to male and female breeding rats in an oral dose-range of 1-100x the recommended maximum human dose produced dose-related pre-and post-implantation losses and a significant decrease in the number of live pups born at the highest dose. These findings suggest the possibility of a general adverse effect on fertility in males and females. In a 24-mo rat carcinogenicity study, oral diclofenac Na was not tumorigenic at 0.08xthe recommended maximum human dose of 148 mg/m 2 /day. In a 24-mo mouse carcinogenicity study, oral diclofenac Na at doses up to 0.006x the recommended maximum human dose in males and 0.02 x the recommended maximum human dose in females was not tumorigenic. Diclofenac Na at oral doses up to 0.16x the recommended maximum human dose was found to have no effect on fertility and reproductive performance of male and female rats. Pregnancy: Pregnancy category X: See boxed CONTRAINDICA-TIONS AND WARNINGS regarding misoprostol. ARTHROTEC is contraindicated in pregnancy.
INDICATIONS AND USAGE
Non-teratogenic effects:
Misoprostol may endanger pregnancy (may cause miscarriage) and thereby cause harm to the fetus when administered to a pregnant woman. Misoprostol produces uterine contractions, uterine bleeding, and expulsion of the products of conception. Miscarriages caused by misoprostol may be incomplete. In studies in women undergoing elective termination of pregnancy during the first trimester, misoprostol caused partial or complete expulsion of the products of conception in 11% of the subjects and increased uterine bleeding in 41%. Reports, primarily from Brazil, of congenital anomalies and reports of fetal death subsequent to misuse of misoprostol alone, as an abortifacient, have been received (see CONTRAINDICATIONS AND WARNINGS). If a woman is or becomes pregnant while taking this drug, the drug should be discontinued and the patient apprised of the potential hazard to the fetus. The diclofenac Na component of ARTHROTEC, like other NSAIDs which are prostaglandin-inhibiting drugs, may affect the fetal cardiovascular system causing premature closure of the ductus arteriosus. NSAIDs may also inhibit uterine contractions. Teratogenic effects: Animal tests have revealed no evidence of teratogenic potential for ARTHROTEC, misoprostol, or diclofenac. Nursing mothers: Because of the potential for serious adverse reactions in nursing infants, ARTHROTEC is not recommended for use by nursing mothers.
Pediatric use: Safety and effectiveness in pediatric patients have not been established. Geriatric use: In clinical trials, no overall differences in safety and effectiveness were observed between subjects >65 years of age and younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. As with any NSAID, the elderly are likely to tolerate adverse events less well than younger patients. The risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and renal function monitored (see PRECAUTIONS-Renal effects). Based on studies in the elderly, no dose adjustment is necessary in the elderly for PK reasons, although many elderly may need to receive a reduced dose because of low body weight or disorders associated with aging. ADVERSE REACTIONS Adverse reactions associated with ARTHROTEC Gastrointestinal: In clinical trials, the most frequently reported adverse events were GI disorders: abdominal pain (21%), diarrhea (19%), dyspepsia (14%), nausea (11%), and flatulence (9%). ARTH-ROTEC can cause more Gl symptoms than diclofenac alone. These events led to discontinuation of therapy in 9% of patients. Diarrhea and abdominal pain developed early in the course of therapy, and were usually self-limited (resolved after 2 to 7 days). Rare instances of profound diarrhea leading to severe dehydration have been reported in patients receiving misoprostol. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully. The incidence of diarrhea can be minimized by administering ARTHROTEC with food and by avoiding coadministration with magnesium-containing antacids. Gynecological: Postmenopausal vaginal bleeding may occur (see below) and should be evaluated to rule out gynecologic pathology. Other: Adverse experiences reported occasionally or rarely with ARTHROTEC, diclofenac or other NSAIDs, or misoprostol are: Body as a whole: Asthenia, death, fatigue, fever, infection, malaise, sepsis. Cardiovascular system: Arrhythmia, atrial fibrillation, CHF, hypertension, hypotension, increased CPK, increased LDH, Ml, palpitations, phlebitis, PVCs, syncope, tachycardia, vasculitis. Central and peripheral nervous system: Coma, convulsions, dizziness, drowsiness, headache, hyperesthesia, hypertonia, hypoesthesia, insomnia, meningitis, migraine, neuralgia, paresthesia, somnolence, tremor, vertigo. Digestive: Anorexia, appetite changes, constipation, dry mouth, dysphagia, enteritis, esophageal ulceration, esophagitis, eructation, gastritis, gastroesophageal reflux, Gl bleeding, Gl neoplasm benign, glossitis, heartburn, hematemesis, hemorrhoids, intestinal perforation, peptic ulcer, stomatitis and ulcerative stomatitis, tenesmus, vomiting. Female reproductive disorders: Breast pain, dysmenorrhea, intermenstrual bleeding, leukonhea, menstrual disorder, monorrhagia, vaginal hemorrhage. Hemic and lymphatic system: Agranulocytosis, anemia, aplastic anemia, coagulation time increased, ecchymosis, eosinophilia, epistaxis, hemolytic anemia, leukocytosis, leukopenia, lymphadenopathy, melena, pancytopenia, pulmonary embolism, purpura, rectal bleeding, thrombocythemia, thrombocytopenia. Hypersensitivity:
Angioedema, laryngeal/pharyngeal edema, urticaria. Uver and biliary system: Abnormal hepatic function, bilirubinemia, hepatitis, jaundice, liver failure, pancreatitis. Male reproductive disorders: Impotence, perineal pain. Metabolic and nutritional: Alkaline phosphatase increased, BUN increased, dehydration, glycosuria, gout, hypercholesterolemia, hyperglycemia, hyperuricemia, hypoglycemia, hyponatremia, periorbital edema, porphyria, weight changes. Musculoskeletal system: Arthralgia, myalgia. Psychiatric: Anxiety, concentration impaired, confusion, depression, disorientation, dream abnormalities, hallucinations, irritability, nervousness, paranoia, psychotic reaction. Respiratory system: Asthma, coughing, dyspnea, hyperventilation, pneumonia, respiratory depression. Skin and appendages: Acne, alopecia, bruising, eczema, erythema multiforme, exfoliative dermatitis, pemphigoid reaction, photosensitivity, pruritus, pruritus ani, rash, skin ulceration, Stevens-Johnson syndrome, sweating increased, toxic epidermal necrolysis. Special senses: Hearing impairment, taste loss, taste perversion, tinnitus. Urinary system: Cystitis, dysuria, hematuria, interstitial nephritis, micturition frequency, nocturia, nephrotic syndrome, oliguria/polyuria, papillary necrosis, proteinuria, renal failure, urinary tract infection. Vision: Amblyopia, blurred vision, conjunctivitis, diplopia, glaucoma, iritis, lacrimation abnormal, night blindness, vision abnormal.
OVERDOSAGE
The toxic dose of ARTHROTEC has not been determined. However, signs of overdosage from the components of the product may include: diclofenac-Gl complaints, confusion, drowsiness or general hypotonia; misoprostol-sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Overdosage symptoms should be treated with supportive therapy. In case of acute overdosage, gastric lavage is recommended. Induced diuresis may be beneficial. The use of oral activated charcoal may help to reduce absorption. SPECIAL DOSING CONSIDERATIONS: ARTHROTEC contains misoprostol, which provides protection against gastric and duodenal ulcers. For gastric ulcer prevention, the 200 meg qid and tid regimens are therapeutically equivalent, but more protective than the bid regimen. For duodenal ulcer prevention, the qid regimen is more protective than the tid or bid regimens. However, the qid regimen is less well tolerated than the tid regimen because of usually self-limited diarrhea related to the misoprostol dose (see ADVERSE REACTIONS-Gastrointestinal) , and the bid regimen may be better tolerated than tid in some patients. Dosages may be individualized using the separate products (misoprostol and diclofenac), after which the patient may be changed to the appropriate ARTHROTEC dose. If clinically indicated, misoprostol cotherapy with ARTHROTEC, or use of the individual components to optimize the misoprostol dose and/or frequency of administration, may be appropriate. The total dose of misoprostol should not exceed 800 meg/day, and no more than 200 meg of misoprostol should be administered at any one time. Doses of diclofenac higher than 150 mg/day in OA or higher than 225 mg/day in RA are not recommended. 66 More recent approaches have modified the historically less successful vertical banded gastroplasty by using less-invasive laparoscopic adjustable silicone gastric banding. This technique holds promise, but there are few long-term studies. 67 
DOSAGE AND ADMINISTRATION
• CONCLUSION
The treatment of obesity remains challenging for patients and their physicians. Careful assessment of patients and tailored treatment can often provide weight losses of 5% to 10%, which will significantly reduce health risks. Hopefully, current intense research efforts will lead to more-effective therapies in the near future for this increasingly common and poorly understood chronic disease. E3
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